Colestipol hydrochloride

CLINICAL USE

Hyperlipidaemias, particularly type IIa

DOSE IN NORMAL RENAL FUNCTION

5 g once or twice daily, increased if necessary at intervals of 1–2 months, to a maximum of 30 g daily

PHARMACOKINETICS

Molecular weight :–

%Protein binding :0

%Excreted unchanged in urine : 0

Volume of distribution (L/kg) :Not absorbed

half-life – normal/ESRD (hrs) :Not absorbed

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Not dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAnticoagulants: may enhance or reduce effects of coumarins and phenindioneCiclosporin: No reports of an interaction; however, ciclosporin levels should be carefully monitored if colestipol and ciclosporin are prescribed concurrently, as colestipol may interfere with ciclosporin absorption

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorptionColestipol granules may be administered as a suspension in water or a flavoured vehicleColestipol orange contains 32.5 mg aspartame (18.2 mg phenylalanine) per sachet

OTHER INFORMATION

Colestipol may interfere with the absorption of fat soluble vitamins

Tags: post-by-auto-php